Alnylam Pharmaceuticals
Senior Manager, CMC Project Management - Late Stage (Finance)
Overview
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases with unmet need. Our first medicine, the first-ever RNAi therapeutic, has recently been approved by the FDA in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. In addition, Alnylam has four investigational medicines in late-stage development. www.alnylam.com . Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work in 2015, 2016, 2017 and 2018- four years in a row!
Incumbent provides project management leadership and support to cross functional teams and respective expertise areas responsible for the completion of tasks required for late stage clinical and commercial development of new products. This role is responsible for managing deliverables required to fulfill projects for technical Operation and Quality as well as CMC requirements and timelines for all regulatory submissions. This role collaborates with expertise area representatives to establish and manage timelines, resource loading and risk mitigation plans.
Summary of Key Responsibilities